Burosumab prevents further height deficit in toddlers affected by XLH
Background: X-linked hypophosphatemia (XLH) is a rare disease caused by PHEX variants. Besides rickets, XLH leads to disproportionately short stature, which develops during the first months of life.
Elisa Sala +9 more
doaj +5 more sources
The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study [PDF]
Background X-linked hypophosphataemia (XLH) is a rare, hereditary, progressive and lifelong phosphate wasting disorder characterised by pathological elevations in fibroblast growth factor (FGF) 23 concentration and activity; XLH has an incidence of ...
Raja Padidela +11 more
doaj +2 more sources
Femoral anteversion (FNA) in individuals with X-linked hypophosphatemia (XLH) [PDF]
Background/Introduction: XLH is a rare genetic condition which affects phosphate metabolism, resulting in osteomalacia. Individuals with XLH are also at risk of lower limb deformities and early onset of hip osteoarthritis.
Zange, Jochen +3 more
core +4 more sources
MAPK inhibition and growth hormone: a promising therapy in XLH [PDF]
X-linked hypophosphatemia (XLH) leads to growth retardation and bone deformities, which are not fully avoided by conventional treatment with phosphate and vitamin D analogs.
Fuente, Rocío +23 more
core +5 more sources
Decreased Compressional Sound Velocity Is an Indicator for Compromised Bone Stiffness in X-Linked Hypophosphatemic Rickets (XLH) [PDF]
Objectives: To assess the diagnostic potential of bidirectional axial transmission (BDAT) ultrasound, and high-resolution peripheral quantitative computed tomography (HR-pQCT) in X-linked hypophosphatemia (XLH, OMIM #307800), a rare genetic disorder of ...
Adalbert Raimann +14 more
doaj +2 more sources
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description [PDF]
Background: X-linked hypophosphataemia (XLH) is a rare, inherited, phosphate-wasting disorder that elevates fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D (1,25(OH) 2 D) synthesis.
Maria Luisa Brandi +18 more
doaj +4 more sources
Young XLH Patients-Reported Experience with a Supportive Care Program
Anya Rothenbuhler,1 Iva Gueorguieva,2 Lydia Lichtenberger-Geslin,3 Christelle Audrain,1 Sylvie Soskin,4 Candace Bensignor,5 Sylvie Rossignol,4 Aurélia Bertholet-Thomas,6 Lorelei Naudeau,7 Justine Bacchetta,6 Agnès Linglart1,8 1AP-HP, INSERM ...
Rothenbuhler A +10 more
doaj +4 more sources
Longitudinal Single-Cell Transcriptomic Profiling Reveals Dynamic Immune Cell Alterations During Burosumab Therapy in X-Linked Hypophosphatemia. [PDF]
This longitudinal single‐cell study reveals dynamic immune remodeling during burosumab therapy in pediatric X‐linked hypophosphatemia (XLH), highlighting coordinated changes in T cell subtypes (Th2, Th17, and Treg) and natural killer cell subtypes (NK2 and NK3) and immune pathways linked to osteoclast differentiation and treatment response.
Xie Y +6 more
europepmc +2 more sources
Phenotypes of a family with XLH with a novel PHEX mutation [PDF]
AbstractX-linked hypophosphatemia (XLH) is the most common form of heritable hypophosphatemic rickets. We encountered a 4-year-old boy with a novel variant in the phosphate-regulating neutral endopeptidase homolog X-linked (PHEX) gene who presented with a short stature, genu valgum, and scaphocephaly.
Akiko Yamamoto +4 more
openaire +2 more sources
X-linked hypophosphatemia (XLH) represents the most common form of familial hypophosphatemia. Although significant advances have been made in the treatment of bone pathology, patients undergoing therapy continue to experience significantly decreased oral
Elizabeth Guirado +7 more
doaj +1 more source

